MedSci Healthcare Holdings Limited has announced that its subsidiary, Shanghai MedSci MedTech Co., Ltd., has been awarded a contract for a large-scale real-world study by a Chinese pharmaceutical company. The project, valued at approximately RMB 21 million, aims to systematically evaluate the efficacy and safety of IL-1β monoclonal antibody therapy in patients with acute and intercritical gout through a combined prospective and retrospective observational study. MedSci will utilize its internet-based physician platform, big data, and artificial intelligence technologies to support the project. The company stated that this initiative reflects its ongoing commitment to providing digital solutions for the healthcare sector.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief on September 25, 2025, and is solely responsible for the information contained therein.